HC Wainwright Issues Pessimistic Forecast for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Harmony Biosciences in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $4.07 for the year, down from their prior forecast of $4.66. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ FY2027 earnings at $4.72 EPS, FY2028 earnings at $5.74 EPS and FY2029 earnings at $5.58 EPS.

Several other equities research analysts have also recently weighed in on HRMY. Truist Financial cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Mizuho set a $50.00 price objective on shares of Harmony Biosciences in a research note on Thursday, February 19th. Bank of America decreased their target price on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research report on Wednesday, February 25th. Oppenheimer reaffirmed an “outperform” rating and issued a $62.00 price target on shares of Harmony Biosciences in a report on Monday, November 24th. Finally, Needham & Company LLC reduced their price objective on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $42.67.

Harmony Biosciences Stock Down 1.8%

Shares of HRMY opened at $28.54 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.58. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 10.53, a price-to-earnings-growth ratio of 0.39 and a beta of 0.88. Harmony Biosciences has a 1 year low of $25.52 and a 1 year high of $40.87. The business’s 50 day simple moving average is $36.01 and its 200-day simple moving average is $34.05.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The firm had revenue of $243.78 million during the quarter, compared to analysts’ expectations of $240.04 million. During the same quarter in the prior year, the firm posted $0.85 earnings per share. Harmony Biosciences’s quarterly revenue was up 21.1% on a year-over-year basis.

Insider Activity

In other news, CFO Sandip Kapadia sold 20,961 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $35.92, for a total transaction of $752,919.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 50,640 shares of company stock worth $1,932,256 over the last quarter. 23.60% of the stock is currently owned by insiders.

Institutional Trading of Harmony Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its holdings in shares of Harmony Biosciences by 8.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,830,726 shares of the company’s stock worth $68,507,000 after purchasing an additional 139,145 shares during the last quarter. American Century Companies Inc. grew its stake in Harmony Biosciences by 11.2% in the 3rd quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after acquiring an additional 168,145 shares in the last quarter. State Street Corp increased its position in shares of Harmony Biosciences by 0.5% during the fourth quarter. State Street Corp now owns 1,661,850 shares of the company’s stock worth $62,186,000 after acquiring an additional 8,246 shares during the period. LSV Asset Management increased its position in shares of Harmony Biosciences by 3.9% during the fourth quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock worth $62,008,000 after acquiring an additional 62,200 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Harmony Biosciences by 15.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,491,605 shares of the company’s stock valued at $55,816,000 after acquiring an additional 196,224 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences News Summary

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.